Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis

被引:34
|
作者
Saresella, M. [2 ]
Rolland, A. [3 ]
Marventano, I. [2 ]
Cavarretta, R. [4 ]
Caputo, D. [4 ]
Marche, P. [3 ]
Perron, H. [5 ]
Clerici, M. [1 ,2 ]
机构
[1] Univ Milan, Dept Biomed Sci & Technol, Chair Immunol, I-20090 Milan, Italy
[2] Don C Gnocchi ONLUS Fdn IRCCS, Lab Mol Med & Biotechnol, I-20148 Milan, Italy
[3] CEA, INSERUM, U548, Lab Immunochim, F-38054 Grenoble, France
[4] Don C Gnocchi ONLUS Fdn, IRCCS, Multiple Sclerosis Unit, I-20148 Milan, Italy
[5] GeNeuro, Geneva, Switzerland
关键词
cytokines; ENV-SU protein; human endogenous retroviruses (HERV); immunology; multiple sclerosis; T lymphocytes; ENVELOPE PROTEIN; MSRV; EXPRESSION; LYMPHOCYTES;
D O I
10.1177/1352458508100840
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Human endogenous retroviruses are suggested to play a pathogenic role in multiple sclerosis (MS); one of such retroviruses, the MS-associated retroviral agent (MSRV) has repeatedly been isolated in MS patients. Objective and methods We analyzed cytokine profiles in MSRV envelope protein (MSRV ENV-SU)stimulated peripheral blood mononuclear cells of 30 relapsing-remitting MS patients with either acute (AMS) (n = 13) or stable (SMS) (n = 17) disease. Results suggest that MSRV ENV-SU induces the production of inflammatory cytokines, including tumor necrosis factor-alpha (P < 0.05) and interferon-gamma (P < 0.004) in AMS patients and of interleukin-10 (P < 0.05), an inflammation-dampening cytokine, in SMS individuals. Conclusions These data strengthen the hypothesis indicating that MSRV could be involved in the pathogenesis of MS. Multiple Sclerosis 2009; 15: 443-447. http://msj.sagepub.com
引用
收藏
页码:443 / 447
页数:5
相关论文
共 50 条
  • [31] Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis
    Urshansky, Nataly
    Mausner-Fainberg, Karin
    Auriel, Eitan
    Regev, Keren
    Bornstein, Natan M.
    Karni, Arnon
    JOURNAL OF NEUROIMMUNOLOGY, 2011, 232 (1-2) : 171 - 178
  • [32] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
    Miller, Aaron E.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194
  • [33] Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
    Marriott, James J.
    O'Connor, Paul W.
    REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (03) : 179 - 188
  • [34] Current management of relapsing-remitting multiple sclerosis
    Sedal, L.
    Wilson, I. B.
    McDonald, E. A.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (10) : 950 - 957
  • [35] Attention impairment associated with relapsing-remitting multiple sclerosis patients with mild incapacity
    Balsimelli, Silvia
    Fernanda Mendes, Maria
    Bertolucci, Paulo H. F.
    Tilbery, Charles Peter
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2007, 65 (2A) : 262 - 267
  • [36] Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis
    M. C. Buscarinu
    S. Romano
    R. Mechelli
    R. Pizzolato Umeton
    M. Ferraldeschi
    A. Fornasiero
    R. Reniè
    B. Cerasoli
    E. Morena
    C. Romano
    N. D. Loizzo
    R. Umeton
    M. Salvetti
    G. Ristori
    Neurotherapeutics, 2018, 15 : 68 - 74
  • [37] Fatigue in multiple sclerosis relapsing-remitting form
    Mendes, MF
    Tilbery, CP
    Balsimelli, S
    Felipe, E
    Moreira, MA
    Barao-Cruz, AM
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2000, 58 (2B) : 471 - 475
  • [38] Quality of life in relapsing-remitting multiple sclerosis
    Dayapoglu, Nuray
    Tan, Mehtap
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2011, 27 (01) : 133 - 137
  • [39] Immunomonitoring measures in relapsing-remitting multiple sclerosis
    Matsui, M
    Araya, S
    Wang, HY
    Matsushima, K
    Saida, T
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 148 (1-2) : 192 - 199
  • [40] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114